News >

Denosumab Safe, Effective in Increasing Bone Density in Nonmetastatic Prostate Cancer

Brandon Scalea
Published: Tuesday, Dec 11, 2018

Scott Tagawa, MD

Scott Tagawa, MD

Contrary to previous data, denosumab (Xgeva) was shown to decrease the risk of fracture without a higher incidence of cataracts in patients with nonmetastatic prostate cancer, according to results from a phase III trial presented at the 2018 ESMO Congress.

Men with nonmetastatic prostate cancer who are treated with androgen deprivation therapy (ADT) experience bone loss that may be associated with higher fracture risk and reduced survival. In a previous study, low-dose denosumab significantly increased bone mass and reduced vertebral fracture risk in these patients. However, unlike other randomized trials that evaluated denosumab, this study showed that this drug resulted in an increased development of cataracts in those who received it compared with those who were given placebo, said Scott T. Tagawa, MD, MS.

“We wanted to prove if these [earlier] results were real and not just a fluke, so we undertook this newer study,” Tagawa said.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication